Morgan Stanley keeps target for WuXi AppTec stock at HKD 207.40
Published on 10/16/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSExpansion and reporting timetable
- Morgan Stanley maintained an Overweight rating and an HKD 207.40 target on October 15, 2026.
- WuXi AppTec reported CNY 16.39 billion in second-quarter 2026 revenue and CNY 6.36 billion in net income.
- WuXi AppTec stock traded at EUR 22.21 at 10:36 a.m. CEST at Lang & Schwarz on October 16, 2026.
WuXi AppTec (ISIN CNE100003F19) is preparing an expansion that would add 800 tons of active pharmaceutical ingredient capacity, while Morgan Stanley kept an Overweight rating and an HKD 207.40 target on October 15, 2026. The report also cited 2026 capital expenditure guidance of RMB 7.5 billion to RMB 8.5 billion, according to Futunn.
Capacity growth carries the story
The proposed Changzhou project would expand WuXi STA, the company unit serving active pharmaceutical ingredient production. Morgan Stanley said small-molecule reactor capacity could rise 25 percent from 4,000 to 5,000 cubic meters in 2026, while solid-phase peptide synthesis capacity could increase 30 percent from 100,000 liters to 130,000 liters, according to Futunn.
Three events shape the story
On July 21, 2026, WuXi AppTec was named to the FTSE4Good Index Series for the fourth consecutive year. On October 7, 2026, the company reported first-half revenue of RMB 28.90 billion, up 38.93 percent year over year, and raised its full-year revenue guidance to RMB 58.5 billion to RMB 60.5 billion, according to the company investor-relations page. On October 15, 2026, Morgan Stanley reported the Changzhou expansion and maintained its target, according to Futunn.
What comes next for earnings?
The second-quarter 2026 figures provide the latest operating reference: revenue was CNY 16.39 billion and net income was CNY 6.36 billion. The data also show earnings per share of CNY 2.24 for the quarter. WuXi AppTec has scheduled a board meeting for October 26, 2026 to consider third-quarter results, according to Futunn. The next results announcement is set for October 27, 2026, according to Simply Wall St.
Stock price and reporting dates
For investors, the immediate test is whether the capacity plan remains aligned with the company revenue guidance and the upcoming third-quarter reporting date. The company describes its business as an integrated contract research, development and manufacturing organization serving pharmaceutical and life sciences customers across more than 30 countries.
WuXi AppTec was trading at EUR 22.21 at Lang & Schwarz on October 16, 2026 at 10:36 a.m. CEST. The price was 3.14 percent below the Lang & Schwarz prior close, but a dated Xetra close for the reference comparison was not established.
The further course of trading is shown by the continuously updated real-time quote of WuXi AppTec stock.
WuXi AppTec stock facts
- Company: WuXi AppTec Co., Ltd.
- ISIN: CNE100003F19
- Ticker: 603259.SH and 2359.HK
- Price Lang & Schwarz (as of October 16, 2026, 10:36 a.m. CEST): EUR 22.21
- Sector / Industry: Pharmaceuticals and biotechnology, contract research, development and manufacturing
Market context: Latest market reports.
